Phase 2 Brain Cancer Trial, Recruiting NCT01891318 Sponsor: Case Comprehensive Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT01891318
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have previously been diagnosed with cancer (confirmed by tissue testing), except for small cell lung cancer, lymphoma, or germ cell cancers
  • People whose MRI scan shows between 1 and 4 tumours that have spread to the brain, with at least one tumour measuring more than 20mm and no larger than 50mm at its widest point, and where surgery and a targeted radiation treatment called SRS are considered appropriate options
  • People who have previously had SRS treatment on other brain tumours (not the one being targeted in this trial)
  • People who score 70 or above on the Karnofsky performance scale, which is a medical measure of a person's ability to carry out daily activities (confirm with trial site)

Who may not be able to join:

  • People considered medically unfit to have surgery to remove a brain tumour
  • People who have previously had whole brain radiation therapy
  • People who are unable to have an MRI scan for any medical reason
  • People who have a physical or mental condition that would prevent them from taking part in study activities
  • People who are unable or unwilling to attend all required follow-up appointments
  • People whose treatment planning shows that the optic nerve or the area where the optic nerves cross cannot be kept to a radiation dose of 10 Gray or less
  • People whose tumour is located in the brainstem
  • People whose scans or cell tests show that the cancer has spread to the lining of the brain or spinal cord

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Erin Murphy, MD, Case Comprehensive Cancer Center

Phone: 1-866-223-8100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
3 July 2013
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum tolerated dose (MTD); Proportion of participants without local failure (Phase II)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov